TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Force of Endotracheal Tube Extubation; Esophagus vs. Trachea

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria: American Society of Anesthesiologists (ASA) Class I and II patients ≥18 years, undergoing elective surgical procedures in the Saskatoon acute care hospitals of the Saskatoon Health Region and requiring endotracheal intubation as a component of the anesthetic plan -~Exclusion Criteria: those who are physiologically unstable, if there is urgency to proceed with surgery, patients requiring rapid sequence induction, and those with respiratory distress. The anesthesiologists will be encouraged to exclude patients if for any reason they feel that inclusion puts them at risk.~-

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Esophageal then tracheal intubated patient (Type: EXPERIMENTAL): Esophagus is intentionally intubated with a cuffed endotracheal tube, the cuff inflated to \>30cm water pressure, a force transducer attached, and force of extubation recorded. Then Trachea is intentionally intubated the cuff inflated to \>30cm water pressure, and force of extubation recorded.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Plexa ICD Lead Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Successfully implanted with a BIOTRONIK ICD or CRT-D compatible system along with the Plexa lead no more than 30 days prior to consent~* Able to understand the nature of the registry and provide informed consent~* Available for follow-up visits on a regular basis at the study site for the expected 5 years of follow-up~* Accepts BIOTRONIK Home Monitoring® concept~* Age greater than or equal to 18 years~Exclusion Criteria:~* Enrolled in any investigational cardiac device trial~* Enrolled in BIOTRONIK's QP ExCELs lead study~* Planned cardiac surgical procedures or interventional measures within the next 6 months~* Expected to receive heart transplantation or ventricular assist device within 1 year~* Life expectancy of less than 1 year~* Patients reporting pregnancy at the time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient admitted to the CIC unit for a first episode of acute coronary syndrome, in whom the CIC cardiologist considers that Crestor® -rosuvastatin is the most appropriate statin, in combination with a platelet aggregation inhibitor (Plavix®-clopidogrel)~* Patient giving his/her oral consent to participate in the study.~* Patient not previously treated by a lipid-lowering drug.~Exclusion Criteria:~* Patient with a known history of coronary heart disease.~* Patient whose treatment on discharge comprises only one of the two study treatments~* Patient participating or who has participated in the previous 3 months in a biomedical research study in cardiology.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with aortic valve calcification that will be treated with an aortic valve replacement.~* Age ≤ 65 years.~* Signed and dated informed consent.~Exclusion Criteria:~* Inability to provide informed consent~* Earlier radiation therapy of the thorax~* Severe renal disease (patients in treatment with dialysis)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Low Impact Laparoscopy Concept Versus Conventional Laparoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women over 18 years~* planned surgery procedure : ambulatory laparoscopic hysterectomy~* effective contraception if women of childbearing age~* patients with free, informed and signed consent~Exclusion Criteria:~* disorders leading to an unacceptable risk of postoperative complications sought during the interrogation of the patient (disorders of blood coagulation, disorders of the immune system, progressive diseases ....)~* pregnancy or wish for subsequent pregnancy~* lactating women~* contraindication to laparoscopy~* contraindication to minimally invasive endoscopic techniques~* not eligible for outpatient care~* inability to understand the information given~* a person not affiliated to a social security scheme, or deprived of liberty, or under guardianship.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Impact Laparoscopy (Type: EXPERIMENTAL): Low Impact Laparoscopy is a minimally invasive technique that combines low pressure insufflation (with the Intelligent Flow System (iFS) AirSeal® system) and microcoelioscopy (with specific microtrocards and laparoscopic instruments).
- conventional laparoscopy (Type: ACTIVE_COMPARATOR): conventional laparoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age more than 18 years old~* CKD patient with anti-r-huEpo associated PRCA~Exclusion Criteria:~* Pregnancy or lactating women~* Receiving immunosuppression~* Active infection~* Previous history of allergic reaction to cyclosporine, mycophenolate mofetil, cyclophosphamide, prednisolone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- CSA+MMF (Type: ACTIVE_COMPARATOR): Cyclosporine 100 mg BID combine with Mycophenolate mofetil 750 mg BID for 24 weeks
- Cyclophosphamide + pred (Type: ACTIVE_COMPARATOR): Cyclophosphamide 100 mg QD and prednisolone 1.0 mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic proof of prostatic adenocarcinoma without evidence of regional and/or distant metastasis, clinical stage T1c or T2a with high grade disease (Gleason's 8-10) on initial biopsy, or clinical stage T2b-T2c with Gleason's grade 7 or above with a PSA ≥ 10ng/ml, or clinical stage T3.~* Recent (\< 6 weeks prior to study entry) negative bone scan and MRI of abdomen and pelvis.~* Appropriate surgical candidate for radical prostatectomy and a performance status of \< 2 (Zubrod scale).~* Patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count \> 1,500 and platelet count of \> 100,000, adequate hepatic function with a bilirubin \< 1.5 mg % and SGPT \< 2.5x the upper limits of normal, adequate renal function defined as serum creatinine \< 1.5 x ULN.~* Patients must have normal coagulation profile (PT, PTT) and no history of substantial non-iatrogenic bleeding diatheses. Use of anticoagulants is limited to local use only (for control of central line patency).~* Patients must have no history of congestive heart failure or previous MI within the last 12 months.~Exclusion Criteria:~* Previous or current hormonal treatment, chemotherapy, radiation therapy, immunotherapy or other investigational status drug.~* Unable to tolerate transrectal ultrasound.~* Patients who are not appropriate surgical candidates for radical prostatectomy based on the evaluation of co-existent medical diseases and competing causes of death. Patients with uncontrolled cardiac, hepatic, renal or neurologic/psychiatric disorder are not eligible. Patients with uncontrolled and symptomatic orthostatic hypotension or uncontrolled hypertension are not eligible.~* Patients who are HIV positive or have chronic hepatitis B or C infections are not eligible.~* Patients on oral steroid medications are not eligible.~* Patients with significant arteriosclerotic disease, as defined by a previous arterial bypass claudication limiting activity, or a history of cerebrovascular events within the last year (including TIA) are not eligible.~* Prior severe infusion reaction to a monoclonal antibody.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Data not available PI relocated (Type: OTHER): No verifiable data available, PI relocated

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Elevated Intraocular Pressure in Glaucoma Patients During Femtolaser Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* scheduled bilateral cataract surgery~* bilateral known glaucoma confirmed at the preoperative consultation (glaucoma group) or absence of glaucoma in both eyes at confirmed the preoperative consultation (control group).~Exclusion Criteria:~* ophthalmologic pathology known other than glaucoma~* diabetes~  * untreated hypertension~ * multiple sclerosis~ * Graves' disease~ * sarcoidosis~ * patient taking toxic drug for the optic nerve and the retina~ * neurodegenerative disease~ * all general diseases that can affect the ocular structures~ * eye surgery history~ * patient's opposition to participation in the study, according to the law on research into routine care~ * absence of affiliation to social security or to universal medical coverage~ * legally protected patient~ * pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient with glaucoma (Type: EXPERIMENTAL): Patient eligible for bilateral cataract surgery, with glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with phacoemulsification for the other eye.
- Patient without glaucoma (Type: OTHER): Patient eligible for bilateral cataract surgery, without glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with the phacoemulsification for the other eye.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Epidural Morphine Versus Epidural Fentanyl Infusion Following Cesarean Section

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients having an elective Cesarean section~* Healthy women (ASA I or II)~* Regional anesthesia candidates~Exclusion Criteria:~* Morbid obesity (BMI\>40)~* Sleep apnea~* Age under 18~* Intolerance or addiction to opioids

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Preservative free morphine (Type: ACTIVE_COMPARATOR): This group will receive 3mg of preservative free morphine epidurally during the procedure.
- Fentanyl infusion (Type: ACTIVE_COMPARATOR): This group will receive an epidural infusion of fentanyl (60 micrograms per hour), which will be started during the Cesarean section and which will continue for the next two days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Reach Home and Read

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Families who live within the EDCI zone Families who can read and write in English and/or Spanish Families with children aged 6 months to 12 months at the time of enrollment Children born at \>37 weeks gestation~Exclusion Criteria:~* Parent with severe medical or mental health condition limiting ability to attend appointments Child with severe medical or mental health condition limiting ability to attend appointments or participate in behavioral therapies Parent and child plan to move out of state in the next 6 months, or plan to live in another state for 2 months or longer within the next 6 months (ex., summer vacation).

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 12 Months
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): None
- Reach Home and Read (Type: EXPERIMENTAL): This arm will receive the Reach Home and Read early literacy intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Predicting Long-term Outcomes After Cardiac Arrest by Using Serum NGAL

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients who underwent targeted temperature management after out-of-hospital cardiac arrest.~Exclusion Criteria:~* Patients who did not survived 3 days after cardiac arrest.~* Pre-existing end-stage renal disease or dependence on renal replacement therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- good neurologic outcome (Type: None): Patients with good neurological prognosis after 6 months (CPC 1, 2). serum NGAL is collected.
- poor neurologic outcome (Type: None): Patients with poor neurological prognosis after 6 months (CPC 3, 4, 5). serum NGAL is collected.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* males and non-pregnant female patients over 18 years admitted to the hospital or treated in an outpatient heart failure clinic with the primary diagnosis of acute decompensated heart failure.~* evidence of fluid overload more than 8 kg above their dry weight, and conforming to definition of hypervolemia (at least two of the following findings: more than 1+ pitting edema of the lower extremities, jugular venous pressure more than 10 cm water, pulmonary edema or pleural effusion on chest radiograph consistent with ADHF, ascites, paroxysmal nocturnal dyspnea, or equal or more than 2 pillow orthopnea.~Exclusion Criteria:~* acute coronary syndrome~* documented ischemic cardiomyopathy~* atrial fibrillation~* serum creatinine more than 3.0 mg/dL~* systolic blood pressure less than 90 mmHg~* hematocrit \> 45%~* clinical instability likely to require intravenous vasopressors and/or intravenous vasoactive drugs (such as milrinone, dobutamine, nitroglycerin or nesiritide) during the present hospitalization~* severe pulmonary hypertension or use of pulmonary hypertension drugs (such as sildenafil, bosentan or other endothelin inhibitors)~* patients with documented hypertrophic obstructive cardiomyopathy or restrictive cardiomyopathy,~* patients with severe valvular heart disease,~* patients with recent cocaine use (within one month of presentation)~* patients with heart transplant~* patients with systemic infection~* patients on hemodialysis~* inability to obtain venous access~* contraindications for anticoagulation~* unable to lie flat for at least 20 minutes~* pregnant and breast-feeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrafiltration (Type: ACTIVE_COMPARATOR): Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretics (loop diuretics: furosemide, bumetanide, and/or torsemide). Patients in this arm are randomized to ultrafiltration.
- Diuretic Therapy (Type: ACTIVE_COMPARATOR): Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretic therapy ((loop diuretics: furosemide, bumetanide, and/or torsemide). The myocardial blood flow of patients treated with ultrafiltration will be actively compared to diuretic therapy with either furosemide, bumetanide, and/or torsemide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have histologically proven stage IV metastatic melanoma consisting of at least two lesions~* Patients must have a performance status of \< 2 on Eastern Cooperative Oncology Group scale (see Appendix).~* Patients must have bilirubin \< 1.5 mg/dL, transaminases \< 2.5 X ULN, albumin \> 3 gm/dL, creatinine \< 2.0 mg/dL, adequate pulmonary function by physical exam and pulse oximetry and adequate cardiac reserve (EF \> 50% normal). Patients must have a normal echocardiogram without any evidence of cardiac chamber hypertrophy, dilatation or hypokinesis.~* Patients must give written informed consent prior to registration.~* Females and males must be willing to use an approved form of birth control while on this study and for 2 weeks after completion.~* Patients of ages 18-80 are eligible provided they have stage IV melanoma and are negative for BRAF or have failed BRAF inhibitor treatment or if they have failed or are intolerant to other established therapy known to provide clinical benefit for their condition or if they have been adequately consented and agreed to forgo FDA approved clinically meaningful therapy~Exclusion Criteria:~* Inability to give informed consent because of psychiatric problems, or complicated medical problems.~* Serious concurrent medical problems, uncontrolled infections, or disseminated intravascular coagulopathy (DIC).~* Preexisting cardiovascular disease, the only exception being well controlled essential hypertension with a sitting blood pressure of \<155 systolic and \<90 diastolic without any evidence of structural heart disease or one episode of myocardial infarction \> 8 months ago. A past history of the any of the following are exclusions: congestive heart failure, atrial fibrillation, pulmonary hypertension, anticoagulant drug therapy, thromboembolic events, cardiomyopathy or a myocardial infarction within the past 8 months.~* Pregnant or nursing women will be excluded from study.~* History of congestive heart failure.~* History of cirrhosis of the liver

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A-dmDT390-bisFv(UCHT1) with Ionizing Radiation (Type: EXPERIMENTAL): A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy